Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombinant technology (rFIX) have been developed. They have shown s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiello, Andrea, Mancuso, Maria E., Leone, Serena, Rossi, Letizia, Cioni, Lorenzo, Teruzzi, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768593/
https://www.ncbi.nlm.nih.gov/pubmed/36628322
http://dx.doi.org/10.33393/grhta.2022.2331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768593/
https://www.ncbi.nlm.nih.gov/pubmed/36628322
http://dx.doi.org/10.33393/grhta.2022.2331

Ejemplares similares